AtriCure (ATRC) vs. The Competition Financial Analysis

AtriCure (NASDAQ: ATRC) is one of 84 publicly-traded companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it weigh in compared to its rivals? We will compare AtriCure to related companies based on the strength of its earnings, analyst recommendations, profitability, dividends, risk, institutional ownership and valuation.

Analyst Ratings

This is a breakdown of recent ratings and price targets for AtriCure and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AtriCure 0 1 6 0 2.86
AtriCure Competitors 181 1151 2516 90 2.64

AtriCure currently has a consensus price target of $25.67, suggesting a potential upside of 19.71%. As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 7.73%. Given AtriCure’s stronger consensus rating and higher probable upside, equities analysts plainly believe AtriCure is more favorable than its rivals.

Profitability

This table compares AtriCure and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
AtriCure -19.56% -19.56% -11.91%
AtriCure Competitors -126.42% -36.27% -9.90%

Earnings & Valuation

This table compares AtriCure and its rivals gross revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
AtriCure $166.00 million -$19.62 million -21.23
AtriCure Competitors $827.23 million $159.50 million 72.35

AtriCure’s rivals have higher revenue and earnings than AtriCure. AtriCure is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

AtriCure has a beta of 0.72, indicating that its share price is 28% less volatile than the S&P 500. Comparatively, AtriCure’s rivals have a beta of 1.02, indicating that their average share price is 2% more volatile than the S&P 500.

Institutional & Insider Ownership

82.2% of AtriCure shares are owned by institutional investors. Comparatively, 66.9% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by institutional investors. 10.0% of AtriCure shares are owned by insiders. Comparatively, 11.5% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

About AtriCure

AtriCure, Inc. is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures. It has two primary product lines for cardiac tissue ablation, which include Radio Frequency Ablation Devices and cryoICE Cryoablation System, and a product line for left atrial appendage exclusion. The Company also sells Lumitip dissectors and the Estech line of reusable cardiac surgery (valve) instruments. Its cryoICE cryosurgery product line offers various cryoablation devices. Its AtriClip Left Atrial Appendage Exclusion System is designed to occlude the heart’s left atrial appendage (LAA).

Receive News & Ratings for AtriCure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply